US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
EP2823809B1
(de)
|
2002-06-28 |
2016-11-02 |
Protiva Biotherapeutics Inc. |
Verfahren und Vorrichtung zur Herstellung von Liposomen
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
JP4951338B2
(ja)
|
2003-07-16 |
2012-06-13 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質に封入された干渉rna
|
WO2005089224A2
(en)
|
2004-03-12 |
2005-09-29 |
Alnylam Pharmaceuticals, Inc. |
iRNA AGENTS TARGETING VEGF
|
US7303881B2
(en)
*
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
JP4796062B2
(ja)
|
2004-06-07 |
2011-10-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質封入干渉rna
|
ATE537263T1
(de)
|
2004-06-07 |
2011-12-15 |
Protiva Biotherapeutics Inc |
Kationische lipide und verwendungsverfahren
|
US7807815B2
(en)
*
|
2004-07-02 |
2010-10-05 |
Protiva Biotherapeutics, Inc. |
Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA
|
CA2587411A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
WO2006074546A1
(en)
*
|
2005-01-13 |
2006-07-20 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
JP5042863B2
(ja)
*
|
2005-02-14 |
2012-10-03 |
サーナ・セラピューティクス・インコーポレイテッド |
生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
GB2430881B
(en)
*
|
2005-10-06 |
2010-10-13 |
Ntnu Technology Transfer As |
Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
|
US7838658B2
(en)
|
2005-10-20 |
2010-11-23 |
Ian Maclachlan |
siRNA silencing of filovirus gene expression
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
EA015676B1
(ru)
|
2006-05-11 |
2011-10-31 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии гена pcsk9
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
WO2008001505A1
(fr)
*
|
2006-06-30 |
2008-01-03 |
Hokkaido System Science Co., Ltd. |
Composition pour la pénétration d'acides nucléiques
|
WO2008022468A1
(en)
*
|
2006-08-24 |
2008-02-28 |
British Columbia Cancer Agency Branch |
Compositions and methods for treating myelosuppression
|
WO2008042973A2
(en)
|
2006-10-03 |
2008-04-10 |
Alnylam Pharmaceuticals, Inc. |
Lipid containing formulations
|
JPWO2008087803A1
(ja)
*
|
2007-01-16 |
2010-05-06 |
国立大学法人北海道大学 |
抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
|
EP2117304A4
(de)
*
|
2007-02-07 |
2011-08-24 |
Gradalis Inc |
Verfahren und zusammensetzung zur modulation einer sialsäureproduktion und zur behandlung vererbter einschlusskörper-myopathie
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
GB0707096D0
(en)
*
|
2007-04-12 |
2007-05-23 |
Ntnu Technology Transfer As |
Method
|
JP2010187707A
(ja)
*
|
2007-06-12 |
2010-09-02 |
Hokkaido Univ |
インスリンを封入したイオントフォレーシス用リポソーム製剤
|
US8716255B2
(en)
|
2007-08-10 |
2014-05-06 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
KR100807060B1
(ko)
*
|
2007-08-28 |
2008-02-25 |
고려대학교 산학협력단 |
신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는전달체
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
EP2224912B1
(de)
*
|
2008-01-02 |
2016-05-11 |
TEKMIRA Pharmaceuticals Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
MX2010008394A
(es)
*
|
2008-01-31 |
2010-11-12 |
Alnylam Pharmaceuticals Inc |
Metodos optimizados para administracion de arndc focalizando el gen pcsk9.
|
EA201301171A1
(ru)
*
|
2008-03-05 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов eg5 и vegf
|
NZ588583A
(en)
*
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
EP2281041B1
(de)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Abdämpfen der csn5 genexpression unter verwendung von interferierender rns
|
WO2009129387A2
(en)
*
|
2008-04-16 |
2009-10-22 |
Abbott Laboratories |
Cationic lipids and uses thereof
|
AU2009236306B2
(en)
|
2008-04-17 |
2015-04-02 |
Pds Biotechnology Corporation |
Stimulation of an immune response by enantiomers of cationic lipids
|
CN102065901B
(zh)
*
|
2008-06-19 |
2013-03-06 |
日本新药株式会社 |
药物载体
|
EP2326331A4
(de)
*
|
2008-08-18 |
2013-05-15 |
Merck Sharp & Dohme |
Neue lipidnanopartikel und neue komponenten zur freisetzung von nukleinsäuren
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
CN102245590B
(zh)
|
2008-10-09 |
2014-03-19 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
DK2937418T3
(en)
|
2008-10-20 |
2018-01-22 |
Alnylam Pharmaceuticals Inc |
Compositions and Methods for Inhibiting Transthyretin Expression
|
AU2009320006A1
(en)
|
2008-10-30 |
2010-06-03 |
Peixuan Guo |
Membrane-integrated viral DNA-packaging motor protein connector biosensor for DNA sequencing and other uses
|
CN102292069B
(zh)
*
|
2008-11-26 |
2014-07-30 |
中外制药株式会社 |
囊泡制剂
|
US8957199B2
(en)
|
2008-11-26 |
2015-02-17 |
Chugai Seiyaku Kabushiki Kaisha |
Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
|
US8324368B2
(en)
|
2008-12-10 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
CN102421900B
(zh)
*
|
2009-03-12 |
2015-07-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
|
GB0904941D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
GB0904942D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
US20100285112A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Tatiana Novobrantseva |
Methods of delivering oligonucleotides to immune cells
|
EP2430168B1
(de)
|
2009-05-16 |
2016-12-21 |
Kunyuan Cui |
Zusammensetzung mit kationischen amphiphilen und colipiden zur abgabe von heilmittelmolekülen
|
EP3431076B1
(de)
*
|
2009-06-10 |
2021-10-06 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
IL292615B2
(en)
|
2009-07-01 |
2023-11-01 |
Protiva Biotherapeutics Inc |
Nucleic acid-lipid particles, preparations containing them and their uses
|
US8236943B2
(en)
*
|
2009-07-01 |
2012-08-07 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US9181295B2
(en)
|
2009-08-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
Cationic lipids with various head groups for oligonucleotide delivery
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
EP2480668A2
(de)
|
2009-09-23 |
2012-08-01 |
Protiva Biotherapeutics Inc. |
Zusammensetzungen und verfahren zur ausschaltung von in krebs exprimierten genen
|
EP2488210A4
(de)
|
2009-10-12 |
2014-04-30 |
Smith Holdings Llc |
Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
WO2011056883A1
(en)
|
2009-11-03 |
2011-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
|
CN102712935B
(zh)
|
2009-11-04 |
2017-04-26 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
ME03091B
(de)
|
2009-12-01 |
2019-01-20 |
Translate Bio Inc |
Ausgabe von mrna zur vermehrung von proteinen und enzymen bei humangenetischen erkrankungen
|
WO2011090965A1
(en)
|
2010-01-22 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids for oligonucleotide delivery
|
WO2011109294A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Dicerna Pharmaceuticals, Inc. |
Lipid delivery formulations
|
JP2013528665A
(ja)
|
2010-03-26 |
2013-07-11 |
メルサナ セラピューティックス, インコーポレイテッド |
ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
|
EP3391877A1
(de)
|
2010-04-08 |
2018-10-24 |
The Trustees of Princeton University |
Herstellung von lipidnanopartikeln
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
EP2575895A2
(de)
|
2010-05-24 |
2013-04-10 |
Merck Sharp & Dohme Corp. |
Neuartige kationische aminoalkohollipide zur oligonukleotidabgabe
|
EP2575767B1
(de)
*
|
2010-06-04 |
2017-01-04 |
Sirna Therapeutics, Inc. |
Neuartige kationische lipide mit geringem molekulargewicht zur oligonukleotidabgabe
|
US20130164380A1
(en)
|
2010-06-17 |
2013-06-27 |
Actogenix Nv |
Compositions and methods for treating inflammatory conditions
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のrnaを用いた大型哺乳動物の免疫化
|
ES2934240T3
(es)
|
2010-07-06 |
2023-02-20 |
Glaxosmithkline Biologicals Sa |
Partículas de administración de tipo virión para moléculas de ARN autorreplicantes
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
MX2013000164A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
EP3243526B1
(de)
|
2010-07-06 |
2019-11-27 |
GlaxoSmithKline Biologicals S.A. |
Verabreichung von rna zur auslösung von mehreren immunpfaden
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
BR112013002738A2
(pt)
|
2010-08-04 |
2017-06-27 |
Cizzle Biotechnology Ltd |
métodos e compostos para o diagnóstico e o tratamento do câncer
|
EP3578205A1
(de)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
|
AU2011296062A1
(en)
*
|
2010-08-31 |
2013-04-04 |
Novartis Ag |
Small liposomes for delivery of immunogen-encoding RNA
|
ES2727583T3
(es)
*
|
2010-08-31 |
2019-10-17 |
Glaxosmithkline Biologicals Sa |
Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
|
HUE061068T2
(hu)
|
2010-08-31 |
2023-05-28 |
Glaxosmithkline Biologicals Sa |
Pegilált liposzómák immunogént kódoló RNS szállítására
|
US20130253168A1
(en)
|
2010-08-31 |
2013-09-26 |
Steven L. Colletti |
Novel single chemical entities and methods for delivery of oligonucleotides
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
JP5961170B2
(ja)
|
2010-09-20 |
2016-08-02 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
オリゴヌクレオチドの送達のための新規な低分子量カチオン性脂質
|
AU2011307277A1
(en)
|
2010-09-30 |
2013-03-07 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
CA2813466A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
|
BR112013008700B8
(pt)
|
2010-10-11 |
2022-10-04 |
Novartis Ag |
Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
|
EP3485913A1
(de)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Kationische lipide mit geringem molekulargewicht zur oligonukleotidabgabe
|
WO2012058210A1
(en)
*
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
TW201309621A
(zh)
*
|
2011-02-08 |
2013-03-01 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
EP2691101A2
(de)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
US8747891B2
(en)
|
2011-05-10 |
2014-06-10 |
The Penn State Research Foundation |
Ceramide anionic liposome compositions
|
PE20140797A1
(es)
|
2011-06-08 |
2014-07-11 |
Shire Human Genetic Therapies |
COMPOSICIONES Y METODOS PARA ADMINISTRACION DE ARNm
|
EP2718269B1
(de)
|
2011-06-08 |
2018-01-31 |
Translate Bio, Inc. |
Spaltbare lipide
|
US11896636B2
(en)
|
2011-07-06 |
2024-02-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
CA2840977A1
(en)
*
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Liposomes having useful n:p ratio for delivery of rna molecules
|
AU2012301715B2
(en)
*
|
2011-08-31 |
2017-08-24 |
Glaxosmithkline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding RNA
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
KR102014061B1
(ko)
|
2011-10-03 |
2019-08-28 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
|
MX2014004516A
(es)
|
2011-10-11 |
2015-01-16 |
Brigham & Womens Hospital |
Micro-arns en trastornos neurodegenerativos.
|
EP3069785A1
(de)
|
2011-10-25 |
2016-09-21 |
The University Of British Columbia |
Lipidnanopartikel von begrenzter grösse und verfahren dafür
|
JP6165158B2
(ja)
|
2011-11-18 |
2017-07-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスサイレチン(TTR)関連疾患を治療するためのRNAi剤、組成物、およびこれらの使用方法
|
EP2788006A1
(de)
|
2011-12-07 |
2014-10-15 |
Alnylam Pharmaceuticals, Inc. |
Bioabbaubare lipide zur wirkstofffreisetzung
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
US20140045913A1
(en)
*
|
2011-12-12 |
2014-02-13 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nano particles comprising combination of cationic lipid
|
TWI594767B
(zh)
*
|
2011-12-12 |
2017-08-11 |
協和醱酵麒麟有限公司 |
含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
|
LT2791160T
(lt)
|
2011-12-16 |
2022-06-10 |
Modernatx, Inc. |
Modifikuotos mrnr sudėtys
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
LT2817287T
(lt)
|
2012-02-24 |
2018-12-27 |
Arbutus Biopharma Corporation |
Trialkilo katijoniniai lipidai ir jų panaudojimo būdai
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
AU2013243947A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9402816B2
(en)
|
2012-04-19 |
2016-08-02 |
Sima Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery
|
EP2841572B1
(de)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetische korrektur mutierter gene
|
ES2864878T3
(es)
|
2012-06-08 |
2021-10-14 |
Translate Bio Inc |
Administración pulmonar de ARN, a células objetivo no pulmonares
|
EP3536787A1
(de)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nukleaseresistente polynukleotide und verwendungen davon
|
JP6108197B2
(ja)
|
2012-07-02 |
2017-04-05 |
日油株式会社 |
三級アミノ基含有脂質の製造方法
|
CN105101991A
(zh)
|
2012-09-21 |
2015-11-25 |
Pds生物科技公司 |
改进的疫苗组合物和使用方法
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
CN105164264B
(zh)
|
2012-12-12 |
2021-05-07 |
布罗德研究所有限公司 |
用于序列操纵和治疗应用的系统、方法和组合物的递送、工程化和优化
|
MX365409B
(es)
|
2013-03-14 |
2019-05-31 |
Shire Human Genetic Therapies |
Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados.
|
DK2970955T3
(en)
|
2013-03-14 |
2019-02-11 |
Translate Bio Inc |
METHODS FOR CLEANING MESSENGER RNA
|
EA201591293A1
(ru)
|
2013-03-14 |
2016-02-29 |
Шир Хьюман Дженетик Терапис, Инк. |
Способы и композиции для доставки антител, кодируемых мрнк
|
ES2670529T3
(es)
|
2013-03-15 |
2018-05-30 |
Translate Bio, Inc. |
Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
|
CN105143456A
(zh)
|
2013-03-15 |
2015-12-09 |
不列颠哥伦比亚大学 |
用于转染的脂质纳米粒子和相关方法
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
KR102109188B1
(ko)
|
2013-04-01 |
2020-05-11 |
삼성전자주식회사 |
양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
|
CN107995927B
(zh)
|
2013-06-17 |
2021-07-30 |
布罗德研究所有限公司 |
用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
|
CA2915795C
(en)
|
2013-06-17 |
2021-07-13 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
ES2767318T3
(es)
|
2013-06-17 |
2020-06-17 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas
|
JP6620093B2
(ja)
*
|
2013-07-23 |
2019-12-11 |
アービュートゥス バイオファーマ コーポレイションArbutus Biopharma Corporation |
メッセンジャーrnaを送達するための組成物及び方法
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
MX2016004249A
(es)
|
2013-10-03 |
2016-11-08 |
Moderna Therapeutics Inc |
Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
|
WO2015061491A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
NZ718817A
(en)
|
2013-10-22 |
2020-07-31 |
Massachusetts Inst Technology |
Lipid formulations for delivery of messenger rna
|
US20150110857A1
(en)
|
2013-10-22 |
2015-04-23 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
EP3060303B1
(de)
|
2013-10-22 |
2018-11-14 |
Translate Bio, Inc. |
Mrna-therapie für argininosuccinat-synthase-mangel
|
SG10201804977UA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Particle Delivery Components
|
EP3080259B1
(de)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Konstruktion von systemen, verfahren und optimierte führungszusammensetzungen mit neuen architekturen zur sequenzmanipulation
|
JP2017527256A
(ja)
|
2013-12-12 |
2017-09-21 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
HBV及びウイルス性疾患及び障害のためのCRISPR−Cas系及び組成物の送達、使用及び治療適用
|
CN106061510B
(zh)
|
2013-12-12 |
2020-02-14 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
CA2932472A1
(en)
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
EP3134131B1
(de)
|
2014-04-23 |
2021-12-22 |
ModernaTX, Inc. |
Nukleinsäureimpfstoffe
|
CN106164248B
(zh)
|
2014-04-25 |
2019-10-15 |
川斯勒佰尔公司 |
信使rna的纯化方法
|
EP3148552B1
(de)
|
2014-05-30 |
2019-07-31 |
Translate Bio, Inc. |
Biologisch abbaubare lipide zur freisetzung von nukleinsäuren
|
JP6779866B2
(ja)
|
2014-06-13 |
2020-11-04 |
チルドレンズ メディカル センター コーポレイション |
ミトコンドリアを単離するための製品および方法
|
CN111588695A
(zh)
|
2014-06-24 |
2020-08-28 |
川斯勒佰尔公司 |
用于递送核酸的立体化学富集组合物
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2015283954B2
(en)
|
2014-07-02 |
2020-11-12 |
Translate Bio, Inc. |
Encapsulation of messenger RNA
|
DK3180426T3
(da)
|
2014-08-17 |
2020-03-30 |
Broad Inst Inc |
Genomredigering ved anvendelse af cas9-nickaser
|
CA2958542C
(en)
*
|
2014-08-18 |
2022-06-28 |
Nof Corporation |
Cationic lipid for nucleic acid delivery
|
KR20220087571A
(ko)
|
2014-08-29 |
2022-06-24 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
CN107208095B
(zh)
|
2014-10-02 |
2021-11-16 |
阿布特斯生物制药公司 |
用于使乙型肝炎病毒基因表达沉默的组合物和方法
|
MA56412A
(fr)
|
2014-12-05 |
2022-05-04 |
Translate Bio Inc |
Thérapie par l'arn messager pour le traitement des maladies articulaires
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
EP3702456A1
(de)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr mit destabilisierungsdomänen oder mit destabilisierungsdomänenassoziierung
|
CA2975371C
(en)
|
2015-01-30 |
2024-02-13 |
Nof Corporation |
Cationic lipid for nucleic acid delivery
|
EP3900702A1
(de)
|
2015-03-19 |
2021-10-27 |
Translate Bio, Inc. |
Mrna-therapie für morbus pompe
|
US11298326B2
(en)
*
|
2015-03-24 |
2022-04-12 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
EP4026568A1
(de)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilisierung von rna
|
EP3297682B1
(de)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Trockenpulverzusammensetzung mit langkettiger rna
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
AU2016279077A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
IL293323B2
(en)
|
2015-06-18 |
2024-01-01 |
Massachusetts Inst Technology |
CRISPR enzyme mutations that reduce unintended effects
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
JP7072386B2
(ja)
|
2015-06-29 |
2022-05-20 |
アクイタス セラピューティクス インコーポレイテッド |
核酸の送達のための脂質および脂質ナノ粒子製剤
|
EP3329003A2
(de)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
|
IL296476B1
(en)
|
2015-07-31 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
Preparations of transthyretin (TTR) iRNA and methods of using them for the treatment or prevention of TTR-related diseases
|
US9856481B2
(en)
|
2015-08-13 |
2018-01-02 |
Ann & Robert H. Lurie Children's Hospital |
MicroRNA treatment of fibrosis
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
AU2016308339A1
(en)
|
2015-08-18 |
2018-04-12 |
Baylor College Of Medicine |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
BR112018003784A2
(pt)
|
2015-08-24 |
2018-09-25 |
Halo-Bio Rnai Therapeutics, Inc. |
nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização
|
AU2016324310B2
(en)
|
2015-09-17 |
2021-04-08 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
JP6997704B2
(ja)
|
2015-10-14 |
2022-02-04 |
トランスレイト バイオ, インコーポレイテッド |
生産性向上のためのrna関連酵素の修飾
|
EP3365441A1
(de)
|
2015-10-22 |
2018-08-29 |
The Broad Institute Inc. |
Crispr-enzyme des typs vi-b und systeme
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
EP3368507B1
(de)
|
2015-10-28 |
2022-12-07 |
Acuitas Therapeutics Inc. |
Neuartige lipide und lipidnanopartikelformulierungen zur freisetzung von nukleinsäuren
|
AU2016354590B2
(en)
|
2015-11-13 |
2023-11-23 |
Pds Biotechnology Corporation |
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
|
WO2017095940A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes from cultured cells
|
RS63336B1
(sr)
|
2015-12-10 |
2022-07-29 |
Modernatx Inc |
Kompozicije i postupci za isporuku terapijskih agenasa
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
HUE057877T2
(hu)
|
2015-12-22 |
2022-06-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
US10266843B2
(en)
|
2016-04-08 |
2019-04-23 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
US20210155911A1
(en)
|
2016-04-19 |
2021-05-27 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
AU2017253107B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
CPF1 complexes with reduced indel activity
|
AU2017257274B2
(en)
|
2016-04-19 |
2023-07-13 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
WO2017196979A1
(en)
*
|
2016-05-10 |
2017-11-16 |
The Regents Of The University Of Michigan |
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
|
IL263079B2
(en)
|
2016-05-18 |
2024-05-01 |
Modernatx Inc |
Relaxin-encoding polynucleotides
|
AU2017283479B2
(en)
|
2016-06-13 |
2023-08-17 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
|
WO2017219027A1
(en)
|
2016-06-17 |
2017-12-21 |
The Broad Institute Inc. |
Type vi crispr orthologs and systems
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
MX2018016389A
(es)
|
2016-06-30 |
2019-08-16 |
Arbutus Biopharma Corp |
Composiciones y metodos para suministro de arn mensajero.
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CN110114461A
(zh)
|
2016-08-17 |
2019-08-09 |
博德研究所 |
新型crispr酶和系统
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
JP6980780B2
(ja)
|
2016-10-21 |
2021-12-15 |
モデルナティーエックス, インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
EP3532103A1
(de)
|
2016-10-26 |
2019-09-04 |
Acuitas Therapeutics, Inc. |
Lipidnanopartikelformulierung
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
EP3538067A1
(de)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilisierte formulierungen von lipidnanopartikeln
|
EP3585417B1
(de)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Methode der herstellung von codon-optimierter cftr-mrna
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
EP4361261A2
(de)
|
2017-03-15 |
2024-05-01 |
The Broad Institute Inc. |
Neuartige cas13b-orthologe crispr-enzyme und systeme
|
LT3596041T
(lt)
|
2017-03-15 |
2023-01-25 |
Modernatx, Inc. |
Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
US11433026B2
(en)
*
|
2017-03-31 |
2022-09-06 |
University Of Rhode Island Board Of Trustees |
Nanoparticle-induced fusogenicity between liposome and endosome membranes for targeted delivery through endosomal escape
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
KR20200006054A
(ko)
|
2017-04-12 |
2020-01-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규 타입 vi crispr 오르소로그 및 시스템
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
CN116693411A
(zh)
|
2017-04-28 |
2023-09-05 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
WO2018208728A1
(en)
|
2017-05-08 |
2018-11-15 |
Flagship Pioneering, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
KR20200038236A
(ko)
|
2017-06-13 |
2020-04-10 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
큐론을 포함하는 조성물 및 그의 용도
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
EP3675817A1
(de)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Verfahren zur herstellung von lipidnanopartikeln
|
CA3085442A1
(en)
|
2017-09-19 |
2019-03-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
JP2020535802A
(ja)
|
2017-09-21 |
2020-12-10 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化核酸編集のための系、方法、及び組成物
|
EP3692152A4
(de)
|
2017-10-04 |
2021-12-01 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
US20200331841A1
(en)
|
2017-12-28 |
2020-10-22 |
Takeda Pharmaceutical Company Limited |
Cationic lipids
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
US10736847B2
(en)
*
|
2018-07-03 |
2020-08-11 |
Becton, Dickinson And Company |
Inverting device for liposome preparation by centrifugation
|
AU2019318079A1
(en)
|
2018-08-07 |
2021-01-28 |
Massachusetts Institute Of Technology |
Novel Cas12b enzymes and systems
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
US20210317429A1
(en)
|
2018-08-20 |
2021-10-14 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
CN112930396B
(zh)
|
2018-08-24 |
2024-05-24 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
CA3113449A1
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
BR112021006539A2
(pt)
|
2018-10-09 |
2021-07-06 |
Univ British Columbia |
composições e sistemas competentes de vesículas competentes para transfecção isentas de solventes e detergentes orgânicos e métodos relacionados às mesmas
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
US20220177863A1
(en)
|
2019-03-18 |
2022-06-09 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
WO2021030701A1
(en)
|
2019-08-14 |
2021-02-18 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
WO2021195214A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
CN115667531A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒DNA载体和其用于表达戈谢(Gaucher)治疗剂的用途
|
BR112022019769A2
(pt)
|
2020-03-30 |
2022-12-13 |
BioNTech SE |
Composições de rna que direcionam claudina-18.2
|
CN116348149A
(zh)
|
2020-06-15 |
2023-06-27 |
全国儿童医院研究所 |
用于肌营养不良症的腺相关病毒载体递送
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
KR20230056669A
(ko)
|
2020-07-27 |
2023-04-27 |
안자리움 바이오사이언시스 아게 |
Dna 분자의 조성물, 이의 제조 방법 및 이의 사용 방법
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
WO2022223556A1
(en)
|
2021-04-20 |
2022-10-27 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
EP4329884A1
(de)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Nichtvirale dna-vektoren zur expression von anti-coronavirus-antikörpern und verwendungen davon
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスdnaベクター及びその使用
|
EP4353268A1
(de)
|
2021-06-11 |
2024-04-17 |
Nibec Co., Ltd. |
Nanopartikel mit peptid-lipid-konjugat zur abgabe eines oligonukleotids in eine zielzelle und pharmazeutische zusammensetzung damit
|
EP4352215A1
(de)
|
2021-06-11 |
2024-04-17 |
LifeEDIT Therapeutics, Inc. |
Rna-polymerase-iii-promotoren und verfahren zur verwendung
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
US20230046606A1
(en)
|
2021-07-15 |
2023-02-16 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
WO2023288285A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
US20230044997A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
EP4377459A2
(de)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
|
EP4377460A1
(de)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der expression von methyl-cpg-bindendem protein 2 (mecp2)
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其使用方法
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
TW202325263A
(zh)
|
2021-09-14 |
2023-07-01 |
美商雷納嘉德醫療管理公司 |
非環狀脂質及其使用方法
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
CA3235867A1
(en)
|
2021-10-22 |
2023-04-27 |
Munir MOSAHEB |
Mrna vaccine composition
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
AU2022394985A1
(en)
|
2021-11-16 |
2024-05-30 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
CA3238758A1
(en)
|
2021-11-22 |
2023-05-25 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
AU2022398450A1
(en)
|
2021-11-23 |
2024-06-06 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
CA3241014A1
(en)
|
2021-12-20 |
2023-06-29 |
Munir MOSAHEB |
Mrna therapeutic compositions
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023147090A1
(en)
|
2022-01-27 |
2023-08-03 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023183616A1
(en)
|
2022-03-25 |
2023-09-28 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
WO2023215481A1
(en)
|
2022-05-05 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
WO2023230587A2
(en)
*
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
TW202411426A
(zh)
|
2022-06-02 |
2024-03-16 |
美商斯奎柏治療公司 |
經工程化的2類v型crispr系統
|
WO2023240074A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023240076A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
WO2024049979A2
(en)
|
2022-08-31 |
2024-03-07 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064934A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024074634A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
US20240173426A1
(en)
|
2022-11-14 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
WO2024119039A2
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticles and uses thereof
|
WO2024119051A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|